Next Article in Journal
Optimization of Stress-Based Microfluidic Testing for Methicillin Resistance in Staphylococcus aureus Strains
Next Article in Special Issue
Aneuploid CTC and CEC
Previous Article in Journal
Synthesized Mammography: Clinical Evidence, Appearance, and Implementation
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessOpinion
Diagnostics 2018, 8(2), 23; https://doi.org/10.3390/diagnostics8020023

Perspective on Cancer Therapeutics Utilizing Analysis of Circulating Tumor Cells

1
R&D Division, Metimedi Pharmaceuticals Co., 263, Central-ro, Yeonsu-Gu, Incheon 22006, Korea
2
Gachon Institute of Pharmaceutical Science, Gachon University, 191, Hambangmoe-ro, Yeonsu-gu, Incheon 21936, Korea
*
Authors to whom correspondence should be addressed.
Received: 19 March 2018 / Revised: 3 April 2018 / Accepted: 9 April 2018 / Published: 11 April 2018
(This article belongs to the Special Issue Circulating Tumor Cells as Cancer Diagnostic Biomarkers)
Full-Text   |   PDF [250 KB, uploaded 3 May 2018]   |  

Abstract

Various methods are available for cancer screening, and the methods are performed depending on the origin site of cancer. Among these methods, biopsy followed by medical imaging is the most common. After cancer progression is determined, an optimal treatment—such as surgery, chemotherapy, and/or radiation therapy—is selected. A new assay has been developed that detects circulating tumor cells (CTCs). Tracking changes in CTCs may reveal important tumoral sensitivity information or resistance patterns to specific regimens and prompt changes in therapy on a personalized basis. Characterization of CTCs at the DNA, RNA, and protein levels is important for gaining insight for clinical applications. A small number of CTCs can be analyzed to obtain genome information such as the progression of cancer including metastasis, even in a single cluster. Although many clinical studies, particularly CTC enumeration and detection of specific oncogene expression, have increased the success rate of diagnosis and predicting prognosis, there is no consensus regarding the technical approaches and various aspects of the methodology, making it difficult to standardize optimal methods for CTC analysis. However, ongoing technological advances are currently being achieved and large-scale clinical studies are being conducted. Applying CTC analysis in the clinic would be very useful for advancing diagnosis, prognosis prediction, and therapeutics. View Full-Text
Keywords: solid cancer; circulating tumor cells; cancer screening; cancer diagnosis; cancer therapeutics solid cancer; circulating tumor cells; cancer screening; cancer diagnosis; cancer therapeutics
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Jeong, K.-Y.; Kim, E.K.; Park, M.H.; Kim, H.M. Perspective on Cancer Therapeutics Utilizing Analysis of Circulating Tumor Cells. Diagnostics 2018, 8, 23.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top